The deal allows Merck to take over development of privately held LaNova Medicines' LM-299, the companies said on Thursday.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...

The deal allows Merck to take over development of privately held LaNova Medicines' LM-299, the companies said on Thursday. The drug candidate targets a protein called PD-1, which prevents the ...